www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/16150

Title: European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia
Authors: Averbuch, Diana
Orasch, Christina
Cordonnier, Catherine
Livermore, David M.
Mikulska, Malgorzata
Viscoli, Claudio
GYSSENS, Inge
Kern, Winfried V.
Klyasova, Galina
Marchetti, Oscar
Engelhard, Dan
Akova, Murat
Issue Date: 2013
Citation: HAEMATOLOGICA, 98 (12), p. 1826-1835
Abstract: Owing to increasing resistance and the limited arsenal of new antibiotics, especially against Gram-negative pathogens, carefully designed antibiotic regimens are obligatory for febrile neutropenic patients, along with effective infection control. The Expert Group of the 4th European Conference on Infections in Leukemia has developed guidelines for initial empirical therapy in febrile neutropenic patients, based on: i) the local resistance epidemiology; and ii) the patient's risk factors for resistant bacteria and for a complicated clinical course. An 'escalation' approach, avoiding empirical carbapenems and combinations, should be employed in patients without particular risk factors. A 'deescalation' approach, with initial broad-spectrum antibiotics or combinations, should be used only in those patients with: i) known prior colonization or infection with resistant pathogens; or ii) complicated presentation; or iii) in centers where resistant pathogens are prevalent at the onset of febrile neutropenia. In the latter case, infection control and antibiotic stewardship also need urgent review. Modification of the initial regimen at 72-96 h should be based on the patient's clinical course and the microbiological results. Discontinuation of antibiotics after 72 h or later should be considered in neutropenic patients with fever of unknown origin who are hemodynamically stable since presentation and afebrile for at least 48 h, irrespective of neutrophil count and expected duration of neutropenia. This strategy aims to minimize the collateral damage associated with antibiotic overuse, and the further selection of resistance.
Notes: Averbuch, D (reprint author), Hadassah Hebrew Univ, Med Ctr, Pediat Infect Dis Unit, Jerusalem, Israel. dina8282@walla.co.il
URI: http://hdl.handle.net/1942/16150
DOI: 10.3324/haematol.2013.091025
ISI #: 000328545500010
ISSN: 0390-6078
Category: A1
Type: Journal Contribution
Validation: ecoom, 2015
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
published version651.81 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.